两名多发性硬化症患者停用特立氟胺后的反跳综合征。 - Suppr

Suppr

超能文献

Rebound syndrome in two cases of MS patients after teriflunomide cessation.

作者信息

Labauge Pierre, Ayrignac Xavier, Prin Pauline, Charif Mahmoud, Carra-Dalliere Clarisse

机构信息

MS Unit, Department of Neurology, Montpellier University Hospital, Univ Montpellier, INSERM, Montpellier, France.

出版信息

Acta Neurol Belg. 2022 Oct;122(5):1381-1384. doi: 10.1007/s13760-022-01929-w. Epub 2022 Jul 8.

DOI:10.1007/s13760-022-01929-w

PMID:35802339

Abstract

摘要

相似文献

Rebound syndrome in two cases of MS patients after teriflunomide cessation.

Acta Neurol Belg. 2022 Oct;122(5):1381-1384. doi: 10.1007/s13760-022-01929-w. Epub 2022 Jul 8.

Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients?

Rev Neurol (Paris). 2022 Mar;178(3):266-267. doi: 10.1016/j.neurol.2021.06.012. Epub 2021 Sep 24.

Teriflunomide, a potential novel cause of chronic active colitis.

Histopathology. 2020 Dec;77(6):1000-1001. doi: 10.1111/his.14122. Epub 2020 Oct 7.

Teriflunomide: Pediatric First Approval.

Paediatr Drugs. 2021 Nov;23(6):609-613. doi: 10.1007/s40272-021-00471-1.

Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.

Clin Neurol Neurosurg. 2021 Jul;206:106685. doi: 10.1016/j.clineuro.2021.106685. Epub 2021 May 15.

COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.

Mult Scler Relat Disord. 2021 Aug;53:103049. doi: 10.1016/j.msard.2021.103049. Epub 2021 May 30.

Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.

Medicine (Baltimore). 2021 Dec 23;100(51):e28246. doi: 10.1097/MD.0000000000028246.

Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.

Mult Scler. 2020 Nov;26(13):1801-1803. doi: 10.1177/1352458519900961. Epub 2020 Feb 7.

Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.

Mult Scler Relat Disord. 2022 Jul;63:103892. doi: 10.1016/j.msard.2022.103892. Epub 2022 May 16.

Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.

J Neurol Sci. 2017 Sep 15;380:79-81. doi: 10.1016/j.jns.2017.07.014. Epub 2017 Jul 9.

引用本文的文献

Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis.

Heliyon. 2024 May 31;10(11):e31744. doi: 10.1016/j.heliyon.2024.e31744. eCollection 2024 Jun 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Rebound syndrome in two cases of MS patients after teriflunomide cessation.

Acta Neurol Belg. 2022 Oct;122(5):1381-1384. doi: 10.1007/s13760-022-01929-w. Epub 2022 Jul 8.

Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients?

Rev Neurol (Paris). 2022 Mar;178(3):266-267. doi: 10.1016/j.neurol.2021.06.012. Epub 2021 Sep 24.

Teriflunomide, a potential novel cause of chronic active colitis.

Histopathology. 2020 Dec;77(6):1000-1001. doi: 10.1111/his.14122. Epub 2020 Oct 7.

Teriflunomide: Pediatric First Approval.

Paediatr Drugs. 2021 Nov;23(6):609-613. doi: 10.1007/s40272-021-00471-1.

Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.

Clin Neurol Neurosurg. 2021 Jul;206:106685. doi: 10.1016/j.clineuro.2021.106685. Epub 2021 May 15.

COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.

Mult Scler Relat Disord. 2021 Aug;53:103049. doi: 10.1016/j.msard.2021.103049. Epub 2021 May 30.

Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.

Medicine (Baltimore). 2021 Dec 23;100(51):e28246. doi: 10.1097/MD.0000000000028246.

Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.

Mult Scler. 2020 Nov;26(13):1801-1803. doi: 10.1177/1352458519900961. Epub 2020 Feb 7.

Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.

Mult Scler Relat Disord. 2022 Jul;63:103892. doi: 10.1016/j.msard.2022.103892. Epub 2022 May 16.

Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.

J Neurol Sci. 2017 Sep 15;380:79-81. doi: 10.1016/j.jns.2017.07.014. Epub 2017 Jul 9.

引用本文的文献

Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis.

Heliyon. 2024 May 31;10(11):e31744. doi: 10.1016/j.heliyon.2024.e31744. eCollection 2024 Jun 15.